Please login to the form below

Not currently logged in
Email:
Password:

Xenazine

This page shows the latest Xenazine news and features for those working in and with pharma, biotech and healthcare.

FDA approves Teva's Huntington's disease drug at second attempt

FDA approves Teva's Huntington's disease drug at second attempt

The green light gives patients with HD in the US the first alternative to Lundbeck's already approved Xenazine (tetrabenazine) drug, which was launched onto the market in 2008. ... Sales of Xenazine slid by almost a third last year to $225m thanks to the

Latest news

  • FDA sets August review date for Teva's movement disorder drug FDA sets August review date for Teva's movement disorder drug

    Huntington's disease is a much smaller market than TD but that has not stopped the only approved drug for the condition - Lundbeck's Xenazine (tetrabenazine) - bring in sales of $330m

  • FDA turns down Teva's Huntington's disease drug FDA turns down Teva's Huntington's disease drug

    Teva's drug is a 'deuterated' form of VMAT-2 inhibitor tetrabenazine - the active ingredient in Lundbeck's already-approved Xenazine product - with a modified structure that seeks to improve the ... Xenazine is the only approved treatment for

  • Teva drug shows promise in movement disorder Teva drug shows promise in movement disorder

    While there is no FDA-approved drug for TD, the drug from which Teva's candidate is derived - Lundbeck's Xenazine (tetrabenazine) - has been used off-label to treat symptoms but

  • Teva starts M&A push with $3.5bn Auspex buy Teva starts M&A push with $3.5bn Auspex buy

    It is also relatively low risk, as the non-deuterated form of tetrabenazine is already sold as Xenazine by Lundbeck as a treatment for Huntington's and achieved sales of ... Moreover, it may also allow a quick route to market by referencing Xenazine data

  • Lundbeck still feeling effects from Cipralex patent loss Lundbeck still feeling effects from Cipralex patent loss

    Leading the upward trend was Xenazine (tetrabenazine) for the treatment of chorea associated with Huntington's disease - up 27% to 440m krone - and Onfi (clobazam) for Lennox-Gastaut syndrome which added

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics